↓ Skip to main content

Does the kappa opioid receptor system contribute to pain aversion?

Overview of attention for article published in Frontiers in Pharmacology, November 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
5 X users
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
84 Dimensions

Readers on

mendeley
164 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Does the kappa opioid receptor system contribute to pain aversion?
Published in
Frontiers in Pharmacology, November 2014
DOI 10.3389/fphar.2014.00253
Pubmed ID
Authors

Catherine M. Cahill, Anna M. W. Taylor, Christopher Cook, Edmund Ong, Jose A. Morón, Christopher J. Evans

Abstract

The kappa opioid receptor (KOR) and the endogenous peptide-ligand dynorphin have received significant attention due the involvement in mediating a variety of behavioral and neurophysiological responses, including opposing the rewarding properties of drugs of abuse including opioids. Accumulating evidence indicates this system is involved in regulating states of motivation and emotion. Acute activation of the KOR produces an increase in motivational behavior to escape a threat, however, KOR activation associated with chronic stress leads to the expression of symptoms indicative of mood disorders. It is well accepted that KOR can produce analgesia and is engaged in chronic pain states including neuropathic pain. Spinal studies have revealed KOR-induced analgesia in reversing pain hypersensitivities associated with peripheral nerve injury. While systemic administration of KOR agonists attenuates nociceptive sensory transmission, this effect appears to be a stress-induced effect as anxiolytic agents, including delta opioid receptor agonists, mitigate KOR agonist-induced analgesia. Additionally, while the role of KOR and dynorphin in driving the dysphoric and aversive components of stress and drug withdrawal has been well characterized, how this system mediates the negative emotional states associated with chronic pain is relatively unexplored. This review provides evidence that dynorphin and the KOR system contribute to the negative affective component of pain and that this receptor system likely contributes to the high comorbidity of mood disorders associated with chronic neuropathic pain.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 164 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 1%
United States 1 <1%
France 1 <1%
Canada 1 <1%
Unknown 159 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 33 20%
Researcher 24 15%
Student > Master 21 13%
Student > Bachelor 14 9%
Student > Doctoral Student 12 7%
Other 24 15%
Unknown 36 22%
Readers by discipline Count As %
Neuroscience 38 23%
Agricultural and Biological Sciences 20 12%
Medicine and Dentistry 19 12%
Biochemistry, Genetics and Molecular Biology 11 7%
Pharmacology, Toxicology and Pharmaceutical Science 11 7%
Other 22 13%
Unknown 43 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 December 2020.
All research outputs
#5,698,265
of 23,340,595 outputs
Outputs from Frontiers in Pharmacology
#2,269
of 16,802 outputs
Outputs of similar age
#75,897
of 363,686 outputs
Outputs of similar age from Frontiers in Pharmacology
#8
of 56 outputs
Altmetric has tracked 23,340,595 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,802 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 363,686 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 56 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.